<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445600</url>
  </required_header>
  <id_info>
    <org_study_id>115579</org_study_id>
    <nct_id>NCT01445600</nct_id>
  </id_info>
  <brief_title>ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)</brief_title>
  <acronym>ALTARGOPMS</acronym>
  <official_title>An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-centre, non-interventional post-marketing surveillance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multi-centre, non-interventional post-marketing surveillance to
      monitor the safety of ALTARGO(retapamulin) treated in Korean patients according to the
      prescribing information.

      ALTARGO is a trademark of the GlaxoSmithKline group of companies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of adverse event after ALTARGO(retapamulin) treatment</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of unexpected adverse event after ALTARGO(retapamulin) treatment</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of serious adverse event after ALTARGO(retapamulin) treatment</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of ALTARGO(retapamulin) treatment</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3612</enrollment>
  <condition>Skin Infections, Bacterial</condition>
  <arm_group>
    <arm_group_label>ALTARGO(retapamulin)</arm_group_label>
    <description>The subjects with bacterial skin and skin structure infections (SSSI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALTARGO(retapamulin)</intervention_name>
    <description>Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.</description>
    <arm_group_label>ALTARGO(retapamulin)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients administrated ALTARGO(retapamulin) with primary impetigo or secondarily infected
        traumatic lesions in Korea
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must satisfy the following criteria at study entry:

               1. Subjects administered with ALTARGO(retapamulin) in the topical treatment of the
                  following bacterial skin and skin structure infections (SSSI)

               2. Subjects who the investigator believes that they can and will comply with the
                  requirements of the protocol and follow the administration regimen

               3. Subjects administered with ALTARGO(retapamulin) following the locally approved
                  prescribing information

        Exclusion Criteria:

          -  Considering the nature of observational study, GSK Korea encourages the doctors
             participating in this study to enrol the subjects prescribed with retapamulin
             following the locally approved Prescribing Information.

               1. Subjects with a known or suspected hypersensitivity to ALTARGO(retapamulin) or
                  any component of the ointment

               2. Infants under nine months of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impetigo</keyword>
  <keyword>secondarily-infected traumatic lesions</keyword>
  <keyword>retapamulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

